Estääkö postoperatiivisesti annettu kortikosteroidi hiippaläppäleikkauksen jälkeisen eteisvärinän ilmaantumista?

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2007-007085-38-FI

Enrollment

220

Registered

2008-01-31

Start date

2008-05-05

Completion date

Unknown

Last updated

2025-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tutkimukseen otetaan 220 peräkkäistä hiippaläppäleikkaukseen tulevaa potilasta, joilla ennen leikkausta on sinusrytmi. Tutkimukseen valittavilla potilailla on siis sydämen hiippaläpän leikkaushoitoa vaativa sairaus. MedDRA version: 9.1 Level: LLT Classification code 10027729 Term: Mitral valve insufficiency and aortic valve stenosis

Interventions

Trade Name: Solu-Cortef 50 mg/ml Pharmaceutical Form: INN or Proposed INN: HYDROCORTISONE CAS Number: 50237 Pharmaceutical form of the placebo: Injection* Route of administration of the placebo: Intr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026